CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for N4 Pharma PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

N4 Pharma PLC
Weston House, 1 Bradgate Park View
Phone: +44 1332690061p:+44 1332690061 DERBY, DE73 5UJ  United Kingdom Ticker: N4PN4P
Business Summary
N4 Pharma plc is a United Kingdom-based pre-clinical biotech company. The Company is engaged in developing Nuvec, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. The Company is building out its preclinical dataset and working towards first-in-human clinical data to support licensing deals for its Nuvec platform with gene therapy partners. Its lead program, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept program showcasing all the benefits of the Nuvec platform. ECP105 is a siRNA therapy intended for injection into the ocular cavity and contains a proprietary siRNA sequence to silence the fibrotic gene responsible for fibrosis (MRTF-B), or scarring, which occurs post-surgery. LipTide is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
8741 Management services
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board ChristopherBritten 8/1/2023 5/20/2019
Chief Executive Officer, Executive Director Nigel J.Theobald
Executive Director Luke S.Cairns 44 7/15/2020 10/14/2015
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Nanogenics Ltd 2 Woodberry Grove London England United Kingdom

Business Names
Business Name
N4P
Nanogenics Ltd
ONZ

General Information
Number of Employees: 4 (As of 12/31/2024)
Outstanding Shares: 832,280,349 (As of 4/23/2025)
Shareholders: 2,752
Stock Exchange: LON
Fax Number: +44 1279821300


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, September 9, 2025
Register now for our FAST Rating webinar on September 10 at 2:00 PM ET!